[HTML][HTML] Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

MY Lee, A Yeon, M Shahid, E Cho, V Sairam, R Figlin… - Oncotarget, 2018 - ncbi.nlm.nih.gov
MY Lee, A Yeon, M Shahid, E Cho, V Sairam, R Figlin, KH Kim, J Kim
Oncotarget, 2018ncbi.nlm.nih.gov
Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC)
remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant
BC have an extremely poor prognosis. One possible approach that may provide insightful
and valuable information regarding resistance mechanisms is looking into the lipid
metabolism of BC cells. Metabolism of lipids is essential for cancer cells and is associated
with the regulation of a variety of key cellular processes and functions. This study conducted …
Abstract
Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC) remains to be an elusive and difficult disease. Patients with recurrent and chemoresistant BC have an extremely poor prognosis. One possible approach that may provide insightful and valuable information regarding resistance mechanisms is looking into the lipid metabolism of BC cells. Metabolism of lipids is essential for cancer cells and is associated with the regulation of a variety of key cellular processes and functions. This study conducted a comparative lipidomic profiling of two isogenic human T24 bladder cancer cell lines, one of which is clinically characterized as cisplatin-sensitive (T24S) and the other as cisplatin-resistant (T24R). Immunohistochemistry analysis revealed that expression of cytosolic acetyl-CoA synthetase 2 (ACSS2) is positively correlated with aggressive BC. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS) analysis profiled a total of 1,864 lipids and levels of differentially expressed lipids suspected of being associated with cisplatin resistance were determined. In addition, we found that ACSS2 inhibition greatly perturbed levels of metabolites, including CE (18: 1), CE (22: 6), TG (49: 1), and TG (53: 2). This study broadens our current knowledge on the links between cisplatin resistance and lipid metabolism in aggressive BC and suggests potential biomarkers for identifying higher-risk patients.
ncbi.nlm.nih.gov